ProQR Announces Fourth Quarter and Full Year 2021 Operating and Financial Results Press release Additional analyses ongoing from Phase 2/3 Illuminate trial of sepofarsen in LCA10 with updates on any potential next steps with this program and overall strategy anticipated in Q2 2022 Phase 2/3 Sirius and Celeste clinical trials of ultevur February 24, 2022